|

Optimization of Late Imagery Rescripting Research Using Generative Artificial Intelligence

RECRUITINGN/ASponsored by University of Social Sciences and Humanities, Warsaw
Actively Recruiting
PhaseN/A
SponsorUniversity of Social Sciences and Humanities, Warsaw
Started2026-04
Est. completion2026-06
Eligibility
Age18 Years – 35 Years
Healthy vol.Accepted

Summary

The aim of the study is to examine the effect of imagery rescripting (ImRs) in the context of utilizing large language models (LLMs). Intervention will involve the prior presentation of the most aversive fragment of the memory, the so-called 'hotspot.' This intervention will allow for the replication of the effect described by Dibbets and Arntz (2016), according to which the prior activation of the most emotional element of a memory enhances the effectiveness of ImRs. The study is also significant due to another ongoing study in which a substantial number of participants have already been examined; however, due to the exhaustion of funds, it was not possible to utilize the remainder of the recruited sample. Investigating an additional condition will allow for a more complete utilization of the available participant pool and significantly increase the project's scientific value by comparing the traditional ImRs mechanism with its AI-generated version.

Eligibility

Age: 18 Years – 35 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age 18-35
* Score ≥ 8 on GAD-7 (Plummer et al., 2016)
* Ability to recall at least two childhood memories involving parental criticism

Exclusion Criteria:

* History of prolonged physical or sexual abuse
* Current psychotherapy or psychopharmacology
* PTSD diagnosis (DSM-5 screening)
* Substance abuse (TAPS tool)

Conditions4

AnxietyFear of FailureGeneralized AnxietyRumination

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.